DHL COLDCHAIN offers fast, reliable and flexible solutions designed for the Life Science Industry

The life science industry increasingly demands for Europe-wide transport solutions which are able to guarantee product integrity. Being able to offer this, strengthens a global market position. Thus, DHL Freight has been developing the unique DHL COLDCHAIN network.

DHL COLDCHAIN supports its customers by efficient, flexible and most reliable transport solutions along the entire supply chain. By shaping this innovative solution across Europe, DHL Freight becomes the preferred logistics partner for the life science industry.

DHL comprises long-term experience and knowledge gathered by working for major life science companies for numerous years.DHL has been constantly listening to its customers in all major layers in the market sector, and learned their specific requirements and demands concerning transport solutions. Following these guidelines the DHL COLDCHAIN services have been developed. DHL COLDCHAIN is a dedicated, fully monitored and temperature controlled LTL network offering the best possible treatment for sensitive products of this market sector.

DHL COLDCHAIN meets all requirements of the industry in terms of temperature control, security and handling. Its services cover the range of refrigerated (2 – 8° Celsius) as well as controlled ambient products (2 – 25° Celsius).

International temperature controlled network
Throughout Europe, DHL Freight built the infrastructure for demanding products of pharmaceutical and life science industry. A fleet of refrigerated trucks is at your disposal at any time, and ensures the sensitive goods are constantly treated at the right temperature.

Throughout the journey, the temperature of the pharmaceuticals is continuously measured and transmitted via GPS.With our state of-the-art IT tools, this allows each customer to track the status and temperature of all shipments during the entire journey. In addition, all warehouses and cross docking stations are specifically equipped to guarantee continuous temperature control. Of course, they meet all GDP requirements (Good Distribution Practice). In the extension of DHL Freight network of branch offices and cross-docking stations, DHL COLDCHAIN provides the shortest possible lead-times. As an advantage, DHL COLDCHAIN is an LTL (less than truck load) service with fixed departure schedules. By these choices, our customers benefit from our flexibility and costeffectiveness. Even for smaller volumes.

Services

  • Unique DHL COLDCHAIN network across Europe and beyond
  • LTL consolidation service
  • Temperature controlled services for refrigerated (2 – 8° Celsius) as well as controlled ambient products (2 – 25° Celsius)
  • Top quality handling and security services
  • GPS security surveillance
  • Scheduled departures and deliveries
  • Short lead times
  • Central booking and administration
  • Online tracking & tracing
  • Temperature data recording

For further information, please contact:

DHL Freight
Life Science Competence Center
DHL Logistics (Switzerland) Ltd
St. Jakobs-Strasse 224
4052 Basle
Switzerland
Telephone +41 61 315 9191
www.dhl.ch

Most Popular Now

Pfizer receives positive FDA Advisory Committee vo…

Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration's (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted that avail...

Engineered bacteria find tumors, then alert the au…

Combining discoveries in cancer immunology with sophisticated genetic engineering, Columbia University researchers have created a sort of "bacterial suicide squad" that ...

First nasal monoclonal antibody treatment for COVI…

A pilot trial by investigators from Brigham and Women's Hospital, a founding member of the Mass General Brigham healthcare system, tested the nasal administration of the ...

US FDA Advisory Committee votes to support effecti…

GSK plc (LSE/NYSE: GSK) announced that the US Food and Drug Administration (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted that the avail...

"Semantic similarity" leads to novel dru…

The words that researchers use to describe their results can be harnessed to discover potential new treatments for Parkinson's disease, according to a new study published...

Tumour cells' response to chemotherapy is driven b…

Cancer cells have an innate randomness in their ability to respond to chemotherapy, which is another tool in their arsenal of resisting treatment, new research led by the...

Pfizer invests $43 billion to battle cancer

Pfizer Inc. (NYSE: PFE) and Seagen Inc. (Nasdaq: SGEN) today announced that they have entered into a definitive merger agreement under which Pfizer will acquire Seagen, a...

Pfizer's ZAVZPRET™ (zavegepant) migraine nasal spr…

Pfizer Inc. (NYSE: PFE) today announced the U.S. Food and Drug Administration (FDA) has approved ZAVZPRET™ (zavegepant), the first and only calcitonin gene-related peptid...

Gene and cell therapies to combat pancreatic cance…

Pancreatic cancer is an incurable form of cancer, and gene therapies are currently in clinical testing to treat this deadly disease. A comprehensive review of the gene an...

Scientists reveal a potential new approach to trea…

Scientists at the National Institutes of Health and Massachusetts General Hospital in Boston have uncovered a potential new approach against liver cancer that could lead ...

Normalizing tumor blood vessels may improve immuno…

A type of immune therapy called chimeric antigen receptor (CAR)-T cell therapy has revolutionized the treatment of multiple types of blood cancers but has shown limited e...

Digital twin opens way to effective treatment of i…

Inflammatory diseases like rheumatoid arthritis have complex disease mechanisms that can differ from patient to patient with the same diagnosis. This means that currently...